[1]季学清,刘 萍△,陈宝瑾,等.冠心康方加减联合西药治疗冠心病合并2型糖尿病气虚痰瘀证疗效研究*[J].陕西中医,2020,(9):1208-1211.[doi:DOI:10.3969/j.issn.1000-7369.2020.09.008]
　JI Xueqing,LIU Ping,CHEN Baojin,et al.Efficacy of Guanxinkang preparation combined with western medicine in the treatment of coronary heart disease and type 2 diabetes mellitus with syndrome of Qixu Tanyu[J].,2020,(9):1208-1211.[doi:DOI:10.3969/j.issn.1000-7369.2020.09.008]
点击复制

冠心康方加减联合西药治疗冠心病合并2型糖尿病气虚痰瘀证疗效研究*
分享到：

《陕西中医》[ISSN:1000-7369/CN:61-1281/TN]

卷:
期数:
2020年9期
页码:
1208-1211
栏目:
临床研究
出版日期:
2020-09-05

文章信息/Info

Title:
Efficacy of Guanxinkang preparation combined with western medicine in the treatment of coronary heart disease and type 2 diabetes mellitus with syndrome of Qixu Tanyu
作者:
季学清1; 刘 萍1△; 陈宝瑾2; 王赛华3; 富立群3
1.上海中医药大学附属龙华医院(上海 200032); 2.上海市浦东新区浦南医院(上海 200125); 3.上海市浦东新区周浦医院(上海 201318)
Author(s):
JI Xueqing; LIU Ping; CHEN Baojin; et al.
Longhua Hospital Affiliated to Shanghai University of Traditional Chinese Medicine(Shanghai 200032)
关键词:
冠心病;  2型糖尿病;  冠心康方;  气虚痰瘀证;  脉搏波传导速度;  血脂
Keywords:
Coronary heart disease;  Type 2 diabetes mellitus;  Guanxinkang preparation;  Qixu Tanyu syndrome;  Pulse wave conduction velocity;  Blood fat
分类号:
R541.4
DOI:
DOI:10.3969/j.issn.1000-7369.2020.09.008
文献标志码:
A
摘要:
目的:探讨冠心康方加减联合西药治疗冠心病合并2型糖尿病气虚痰瘀证的疗效。方法:选择冠心病合并2型糖尿病患者98例,按随机数字表法分为对照组47例和观察组51例。对照组给予西医常规治疗措施; 观察组在对照组治疗基础上加用冠心康方加减治疗,1剂/次,2 次/d。连续治疗6个月后,比较两组血糖血脂水平、中医证候评分、脉搏波传导速度(PWV)以及临床疗效。结果:治疗后,观察组的空腹血糖(6.71±1.04)mmol/L、餐后2 h血糖为(10.63±1.94)mmol/L、HbA1c(7.13±0.97)%、TG(2.50±0.40)mmol/L,TC(3.94±0.55)mmol/L均低于对照组[(6.89±1.13)mmol/L、(10.93±2.03)mmol/L、(7.22±1.25)%、(2.53±0.36)mmol/L、(4.01±0.53)mmol/L],两组间比较差异有统计学意义(P<0.05)。治疗后观察组HDL-C(1.23±0.22)mmol/L 与对照组(1.19±0.21)mmol/L比较上升,而观察组LDL-C(2.61±0.34)mmol/L比对照组(2.67±0.37)mmol/L下降,组间比较差异无统计学意义(P>0.05)。治疗后,观察组患者中医证候评分(1.76±0.27)分及BS-PWV(5.90±0.64)m/s、ES-PWV(7.59±0.94)m/s均明显低于对照组的[(2.13±0.31)分、(6.41±0.77)m/s、(8.43±1.31)m/s](P<0.05)。观察组和对照组的总有效率分别为70.59%和59.57%,两组比较差异有统计学意义(P<0.05)。结论:冠心康方加减联合西药治疗冠心病合并2型糖尿病气虚痰瘀证可有效改善患者的血糖、血脂、中医证候以及动脉硬化,提高临床疗效。
Abstract:
Objective:To investigate the efficacy of Guanxinkang preparation combined with western medicine in the treatment of coronary heart disease and type 2 diabetes mellitus with syndrome of Qixu Tanyu.Methods:98 coronary heart disease and type 2 diabetes patients were selected and divided into the control group and the observation group according to the random number table method with 47 patients in the observation group and 51 patients in the control group patients.The control group were given with conventional western medicine treatment.The observation group was treated with Guanxinkang preparation(1 dose/d,2 times/d)on the basis of treatment in the control group.After 6 months,blood glucose and lipid levels,scores of traditional Chinese medicine syndrome,pulse wave conduction velocity(PWV),and the efficacy were compared between the two groups.Results:After treatment,the control group fasting blood glucose(6.71±1.04)mmol/L,2 h postprandial blood glucose(10.63±1.94)mmol/L,HbA1c(7.13±0.97)%,TG(2.50±0.40)mmol/L,TC(3.94±0.55)mmol/L,were obviously decreased(P<0.05),while HDL-C(1.23±0.22)mmol/L were increased,LDL-C(2.61±0.34)mmol/L were decreased,but no significant difference(P>0.05).After treatment,score of traditional Chinese medicine(1.76±0.27)score and the BS-PWV(5.90±0.64)m/s and the ES-PWV(7.59±0.94)m/s in the observation group was significantly lower than those of the control group(P<0.05)).The total effective rates of the observation group and the control group were 70.59% and 59.57%,respectively,with statistically significant differences(P<0.05).Conclusion: Guanxinkang preparation combined with western medicine in treating coronary heart disease and type 2 diabetes mellitus with syndrome of Qixu Tanyu can effectively improve the blood glucose,blood lipid,treaditional Chinese medicine syndrome,arteriosclerosis and increase the efficacy.

参考文献/References:

[1] 张志宇,王俊宏.天麦消渴片对2型糖尿病合并冠心病PCI术后血糖、脂代谢及胰岛素的影响[J].陕西中医,2017,38(10):1422-1423.
[2] 曾康华,邵银进,李文峰,等.心脏康复治疗改善稳定性冠心病合并糖尿病患者的预后[J].暨南大学学报:自然科学与医学版,2017,38(6):486-490.
[3] 何 佳,汪 健,胡业彬.益肾活血解毒汤联合调脂药对冠心病合并2型糖尿病患者PAF及CD40/CD40L的影响[J].中国中医急症,2017,26(10):1857-1859.
[4] 邵正斌,黄 平,夏铭蔚,等.300例冠心病合并2型糖尿病患者中医证型与血脂、血糖和心脏超声结果的关系[J].安徽中医药大学学报,2019,38(4):36-39.
[5] 成 玲,李占川,梁俊国.玉液汤加味治疗2型糖尿病合并冠心病的临床分析[J].中国实验方剂学杂志,2019,25(21):78-83.
[6] 中华医学会心血管病学分会,中华心血管病杂志编辑委员会.慢性稳定性心绞痛诊断与治疗指南[J].中华心血管病杂志,2007,35(3):195-207.
[7] 中华医学会糖尿病学分会.中国2型糖尿病防治指南[J].中华内分泌代谢杂志,2014,30(10):899-907.
[8] 国家中医药管理局.中药新药临床研究指导原则(试行)[S].北京:中国医药科技出版社,2002:68-72.
[9] 曾思权,陈伟飞,曾智桓.rs10911021基因多态性与冠心病合并2型糖尿病中氧化应激的关系[J].广东医学,2018,39(23):3507-3510.
[10] 张秦风,巩书文,李 虹,等.中叶素在糖尿病合并冠心病中的作用[J].中国动脉硬化杂志,2018,26(4):424-428.
[11] 张丽丽.探讨冠心病合并糖尿病患者的中医证候分析[J].糖尿病新世界,2016,19(24):116-117.
[12] 袁 鹏,郭晓辰,朱亚萍,等.从“血-脉-心-神”一体观论治冠心病合并糖尿病[J].中医杂志,2018,59(9):746-749.
[13] 于洪伟,刘奇峰,魏岚萍.血浆致动脉硬化指数对冠心病的预测价值[J].中国动脉硬化杂志,2017,25(9):899-903.
[14] 张红梅,金慧实,梁家彩,等.以PWV与ABI为主要内容的无创动脉硬化检测技术临床应用进展[J].中国老年学杂志,2017,37(5):1264-1265.
[15] 张立建.冠心病合并2型糖尿病患者幽门螺杆菌感染状况与踝臂指数及脉搏波传导速度相关性研究[J].陕西医学杂志,2017,46(3):341-343.
[16] 陈为玮,张虹雷,朱小烽,等.不同运动处方干预对中老年2型糖尿病患者左室功能与脉搏波传导速度的影响[J].中国老年学杂志,2019,39(5):1107-1110.
[17] 李宏波,王 晗,殷立平,等.极速成像技术测定高血压患者的脉搏波传导速度及相关影响因素[J].中华高血压杂志,2017,25(5):477-481.
[18] 张 翔,康 宏,路 宁,等.颈股脉搏波传导速度与冠状动脉病变程度的相关性[J].中国动脉硬化杂志,2016,24(6):615-619.

相似文献/References:

[1]朱 薇.通脉调脂方治疗冠心病稳定性心绞痛疗效及对患者血流变、VCAM1〖JZ〗及ICAM1影响的研究*[J].陕西中医,2019,(3):290.
　ZHU Wei..Effect of Tongmai Tiaozhi recipe on the efficacy, Hemorheology, VCAM1 and ICAM1 〖JZ〗in patients with stable angina pectoris of coronary heart disease[J].,2019,(9):290.
[2]时晓华.丹参多酚酸盐注射液辅助介入治疗冠心病 及对患者心、肾功能和心肌损伤的影响*[J].陕西中医,2019,(5):568.
　SHI Xiaohua..Effects of salvianolate injection on cardiac function, renal function, myocardial injury in percutaneous coronary intervention postoperative patients with coronary heart disease[J].,2019,(9):568.
[3]刘 红,张玲燕,杨 玲.血府逐瘀汤治疗冠心病介入术后心绞痛临床研究[J].陕西中医,2019,(5):594.
　LIU Hong,ZHANG Lingyan,YANG Ling..Clinical observation of Xuefu Zhuyu decoction in the treatment of angina pectoris after PCI for coronary heart disease[J].,2019,(9):594.
[4]吕永飞,陈爱莲.益心康泰胶囊治疗冠心病经皮冠状动脉介入术术后疗效及对患者血流变、血管内皮功能的影响*[J].陕西中医,2019,(6):714.
　LV Yongfei,CHEN Ailian..Effect of Yixin Kangtai capsule on the curative effect hemorheology and vascular endothelial function after coronary artery disease PCI[J].,2019,(9):714.
[5]贺建涛,胡宇才,刘 磊.活血通络散治疗冠心病PCI术后心绞痛疗效研究*[J].陕西中医,2019,(7):854.
　HE Jiantao,HU Yucai,LIU Lei..Efficacy observation of Huoxue Tongluo powder in the treatment of angina pectoris after coronary heart disease PCI[J].,2019,(9):854.
[6]解洪涛,张 顺△,曾广伟.当归补血方联合西药治疗冠脉搭桥术后疗效及对患者血瘀证证候评分和凝血功能的影响*[J].陕西中医,2019,(10):1341.
　XIE Hongtao,ZHANG Shun,ZENG Guangwei..Effects of Danggui Buxue prescription combined with western medicine on blood stasis and coagulation function after coronary artery bypass grafting[J].,2019,(9):1341.
[7]索晓菲,王亚红△,王居新,等.软坚通脉汤治疗冠心病PCI术后Ⅱ期心脏康复疗效〖JZ〗及对患者生活质量的影响*[J].陕西中医,2020,(1):29.
[8]李 勤,谢冰昕△,靳 敏,等.从虚、郁、痰、瘀论治2型糖尿病合并非酒精性脂肪肝*[J].陕西中医,2020,(5):653.[doi:DOI:10.3969/j.issn.10007369.2020.05.028]
[9]尹 毅,李小兰△.益气活血汤联合尼可地尔治疗稳定性心绞痛疗效及对患者T淋巴细胞亚群的影响[J].陕西中医,2020,(7):888.[doi:DOI:10.3969/j.issn.10007369.2020.07.014]
[10]陈 明,张梓岗,夏晶晶,等.丹栀逍遥丸加味治疗肝胃郁热型2型糖尿病合并抑郁症临床研究*[J].陕西中医,2020,(9):1269.[doi:DOI:10.3969/j.issn.1000-7369.2020.09.026]

备注/Memo

备注/Memo:
*上海市浦东新区卫生和计划生育委员会联合攻关项目(PW2016D-7)
更新日期/Last Update: 2020-09-08